NouvNeu003
Early-onset Parkinson's Disease
Phase 1Phase I completed
Key Facts
Indication
Early-onset Parkinson's Disease
Phase
Phase 1
Status
Phase I completed
Company
About iRegene Therapeutics
A biotech company developing iPSC-based cell therapies for neurological and retinal diseases using an AI-integrated discovery platform.
View full company profile